Immix Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Immix Biopharma, Inc. (IMMX) on November 26, 2025. The filing relates to the Company's Registration Statement on Form S-3 (No. 333-290725) and serves to update auditor consents for the incorporation by reference of financial statements from the Annual Report on Form 10-K for the year ended December 31, 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding auditor consents and does not contain new financial performance data.
Material Changes
There are no material changes to financial results or operations reported in this filing. The only change is the submission of newly dated consents from the Company's independent registered public accounting firms.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The document is limited to Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
Key Facts for Investor Verification
- Auditor Consents: Newly dated consents were filed for both KMJ Corbin & Company LLP (former auditor) and Crowe LLP (current auditor), dated November 26, 2025.
- Reference Documents: These consents relate to audit reports dated March 29, 2024, and March 24, 2025, respectively, covering the consolidated financial statements in the 2024 Form 10-K.
- Registration Statement: The consents are required for the Company's Form S-3 Registration Statement (No. 333-290725).
- Emerging Growth Company Status: The registrant is identified as an emerging growth company.